 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || RGT-075 / Regor
Enrollment closed: RGT001-075-203: A Study of RGT001-075 in Adult Patients With Obesity (clinicaltrials.gov) - May 29, 2024
P2, N=73, Active, not recruiting, Sponsor: Regor Pharmaceuticals Inc.
Recruiting --> Active, not recruiting
- ||| RGT-075 / Regor
Enrollment open: RGT001-075-203: A Study of RGT001-075 in Adult Patients With Obesity (clinicaltrials.gov) - Apr 4, 2024
P2, N=60, Recruiting, Sponsor: Regor Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| RGT-075 / Regor
New P2 trial: RGT001-075-203: A Study of RGT001-075 in Adult Patients With Obesity (clinicaltrials.gov) - Feb 26, 2024
P2, N=60, Not yet recruiting, Sponsor: Regor Pharmaceuticals Inc.
- | RGT-075 / Regor
Enrollment change, Trial termination: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes (clinicaltrials.gov) - Nov 18, 2023
P2, N=17, Terminated, Sponsor: Regor Pharmaceuticals Inc.
Not yet recruiting --> Recruiting N=420 --> 17 | Active, not recruiting --> Terminated; Terminated due to financial constraint.
- ||| RGT-075 / Regor
Enrollment closed: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes (clinicaltrials.gov) - May 17, 2022
P2, N=420, Active, not recruiting, Sponsor: Regor Pharmaceuticals Inc.
N=420 --> 17 | Active, not recruiting --> Terminated; Terminated due to financial constraint. Recruiting --> Active, not recruiting
- RGT075 / Regor
A Phase 1, Double-Blind, Placebo-Controlled Multiple Escalating Dose Study of RGT-075 Novel Small-Molecule Oral GLP-1 Receptor Agonist in Adults with Type 2 Diabetes (Poster Hall (Halls D-E); Board No. 94) - May 11, 2022 - Abstract #ADA2022ADA_2112;
A Phase 1, randomized, double-blind, placebo-controlled, inpatient study planned multiple daily doses of RGT-075 or matching placebo (6 active/2 placebo per cohort) for up to 28 days in T2DM patients (baseline HbA1c 6-10.5% and concomitant metformin >500 mg/d). RGT-075 GLP1RA oral small molecule (15-180 mg/day) up to 28 days was safe and QD dosing showed promising exploratory efficacy trends despite high baseline variability and short treatment duration.
- RGT075 / Regor
A First-in-Human Study of RGT-075, a Novel, Orally Bioavailable, Small-Molecule GLP-1 Receptor Agonist, in Healthy Adult Subjects (Poster Hall (Halls D-E); Board No. 724) - May 11, 2022 - Abstract #ADA2022ADA_1847;
Overall, single RGT-075 doses between 15-280 mg were safe and well-tolerated in healthy volunteers. Further clinical development of RGT-075 as a once-daily, oral therapy for T2DM is underway.
- RGT075 / Regor
RGT-075, an Orally Efficacious Small Molecule GLP-1R Full Agonist in Cynomolgus Monkey Models (Poster Hall (Halls D-E); Board No. 753) - May 11, 2022 - Abstract #ADA2022ADA_1467;
In food-induced type 2 diabetic monkeys, once-daily oral administration of RGT-075 reduced food intake and fasting plasma glucose levels. Together, these data support the development and advancement of RGT-075 into the clinic as a potential therapeutic for T2D and obesity.
- |||| RGT-075 / Regor
Enrollment open: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes (clinicaltrials.gov) - Apr 19, 2022
P2, N=420, Recruiting, Sponsor: Regor Pharmaceuticals Inc.
Together, these data support the development and advancement of RGT-075 into the clinic as a potential therapeutic for T2D and obesity. Not yet recruiting --> Recruiting
- | RGT-075 / Regor
New P2 trial: A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes (clinicaltrials.gov) - Mar 25, 2022
P2, N=420, Not yet recruiting, Sponsor: Regor Pharmaceuticals Inc.